bioRxivCancer BiologyPreprint
Plasma cells in human pancreatic ductal adenocarcinoma secrete antibodies to self-antigens
M. Yao, J. Preall, J. Yeh, D. Pappin, P. Cifani, Y. Zhao, S. Shen, P. Moresco, B. He, H. Patel, A. Habowski, D. King, K. Raphael, A. Rishi, D. Sejpal, M. Weiss, D. Tuveson, D. Fearon
Abstract
Intratumoral B cell responses are associated with more favorable clinical outcomes in human pancreatic ductal adenocarcinoma (PDAC). However, the antigens driving these B cell responses are largely unknown. We sought to discover these antigens by using single-cell RNA sequencing (scRNA-Seq) and immunoglobulin (Ig) sequencing of tumor-infiltrating immune cells from seven primary PDAC samples. We identified activated T and B cell responses and evidence of germinal center reactions. Ig sequencing identified plasma cell (PC) clones expressing isotype-switched and hyper-mutated Igs, suggesting the occurrence of T cell-dependent B cell responses. We assessed the reactivity of 41 recombinant antibodies that represented the products of 235 PCs and 12 B cells toward multiple cell lines and PDAC tissues, and observed frequent staining of intracellular self-antigens. Three of these antigens were identified: the filamentous actin (F-actin), the nucleic protein, RUVBL2, and the mitochondrial protein, HSPD1. Antibody titers to F-actin and HSPD1 were elevated in the plasma of PDAC patients, and also detectable in healthy donors. Thus, PCs in PDAC produce auto-antibodies reacting with intracellular self-antigens, which may result from promotion of pre-existing, autoreactive B cell responses. These observations indicate that the chronic inflammatory microenvironment of PDAC can support the adaptive immune response.
- organism: human
- assay: scRNA-seq
- assay: proteomics
- research focus: cell type annotation
- research focus: differential expression
- approach: deep learning
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Antigen-presenting type-I conventional dendritic cells facilitate curative checkpoint blockade immunotherapy in pancreatic cancer
K. K. Mahadevan, A. M. Dyevoich, … R. Kalluri·bioRxiv·Mar 5, 2023
- Plectin promotes an aggressive phenotype and represses cytotoxic T cell activity in pancreatic cancer
Cody L. Wolf, Roxanne K. Ruiz, … Kimberly A. Kelly·Frontiers in ImmunologyPeer-reviewed·Aug 17, 2026
- Targeting Tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade
Sapana Bansod, Timothy Hung-Po Chen, … Kian‐Huat Lim·bioRxiv·Oct 8, 2025
- 3D histology reveals that immune response to pancreatic precancers is heterogeneous and depends on global pancreas structure
Ashley L. Kiemen, Cristina Almagro-Pérez, … Denis Wirtz·bioRxiv·Aug 3, 2024
- Single-Cell RNA Sequencing Reveals the Effects of Chemotherapy on Human Pancreatic Adenocarcinoma and its Tumor Microenvironment
G. Werba, D. Weissinger, … D. M. Simeone·bioRxiv·May 24, 2022
- Tumor-intrinsic MHC-II activation in pancreatic ductal adenocarcinoma enhances immune response and treatment efficacy
Canping Chen, Kyle P. Gribbin, … Zheng Xia·bioRxiv·Oct 21, 2025